Glaxo adds Unilever vet to board; Stada's Q1 profits plummet; J&J seeks ethics advice;

@FiercePharma: The FDA Is On A Quest To Rid DTC Drug Ads Of Confounding Fine Print. Forbes article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Billionaire supporter Paulson could help Teva twist Mylan's arm. Report | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) will add Unilever ($UL) vet Manvinder Singh Banga to its board as a non-executive director this September. Release

> Net profit for Germany's Stada dropped 39% in Q1. Report

> Hungarian pharma Richter reported a 61% leap in first-quarter net profit to 15 billion forints ($55.52 million). Report

> Swedish drugmaker Meda posted Q1 core operating profit above expectations on Wednesday and reiterated its outlook for 2015. More

> Johnson & Johnson ($JNJ) will become the first pharma company to formally seek advice from outside medical ethicists on "compassionate use" requests. Report

> German chemicals group BASF has agreed to sell parts of its pharmaceutical ingredients business to Swiss drug contract manufacturer Siegfried Holding for 270 million euros ($306 million), including assumed debt. More

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: Agilent acquires maker of software for diagnostics laboratories. Report | Follow @FierceMedDev

@VarunSaxena2: NIH says viral vector for delivering gene therapy to treat blindness shows promise, Wall Street less sure. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Theranos hired a former Clinton policy adviser as its top lawyer. Bloomberg story | Follow @EmilyWFierce

> Medtronic aims to push insertion of world's tiniest cardiac monitor into the physicians' office. More

> Startup Moximed gets $33M to gain FDA approval of early stage osteoarthritis knee implant. Article

Biotech News

@FierceBiotech: FierceBiotech Radio with Editas Medicine's Katrine Bosley. More | Follow @FierceBiotech

@JohnCFierce: So the operational word for biotech valuations now seems to be 'frothy.' We blew past frothy months ago and now are at 'dizzying.' | Follow @JohnCFierce

> Pfizer taps new R&D leaders as Gutiérrez-Ramos heads back into biotech. Report

> Atlas' new immuno-oncology biotech recruits an AstraZeneca vet to take the reins. Item

> AbbVie gets a 'breakthrough' for one of its top cancer drugs. Article

CRO News

> Biocon's planned CRO IPO could change the tone in India. Item

> Catalent boosts its profits despite some flat revenue. More

> AMRI swings to another loss despite big sales gains. Story

> Quintiles beefs up in bioanalytics ahead of Quest partnership. Article

> Parexel trims its ambitions after a flat quarter. Report

Vaccines News

> Themis rounds up new cash for Chikungunya jab's PhII. News

> Three universities using $1.55M NIH grant to track vaccine attitudes via Twitter. Item

> GSK's vaccine operating profit, margin dive on Novartis fold-in. Story

> Sanofi promises 7% vax sales growth for 2015, despite rocky Q1. Report

> City of Hope, Fortress Biotech form new company to ward off CMV. Article

Pharma Manufacturing News

> Biosimilar manufacturers form group to influence market in U.S. Item

> Hospira whacks first 100 jobs as it shutters Clayton, NC, plant. More

> BASF selling some APIs, three plants to Siegfried. Report

> FDA makes strides in inspection effort but challenges persist. Story

> Manufacturing moves pay off for AMRI. Article

Pharma Asia News

> China kicks press into high gear to knock down talk on higher drug prices. More

> Australia budget is a showdown on cancer drug funding, safety net reach. Report

> Taiwan device maker Apex invests in India and plans more. More

> Afghan battlefield clotting agent makes a comeback in Russia. Article

> Sumitomo Dainippon, Takeda call it quits on Japan Latuda agreement. Story

And Finally... The FDA has granted Roche ($RHHBY) a breakthrough therapy designation for prospect venetoclax for the treatment of people who have relapsed or refractory chronic lymphocytic leukemia (CLL) with a genetic abnormality. Report